This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Nephrotic Syndrome, Mesangiocapillary (MPGN)막증식성 사구체신염 선천성 신증후군 (막증식성 사구체신염 선천성신증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: N04.5 (congenital nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis / membranoproliferative glomerulonephritis types 1 and 3) | Special Copayment Reduction: V263 (rare disease)
B. SynonymsCongenital nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis | Congenital nephrotic syndrome with membranoproliferative glomerulonephritis, type 1, type 3, or NOS
C. Adult onsetLikelihood of first onset in adulthood very low — the congenital classification presupposes onset within the first year of life. Onset after childhood is possible in some carriers of complement gene variants, but congenital cases classified under ICD N04.5 are characterized by onset at an early age.
1. History1960s: MPGN type 1 and type 3 histologic types described; 2012: Sethi & Fervenza proposed immunofluorescence-based reclassification into C3 glomerulopathy / immune complex-mediated MPGN
2. CausesAutoimmune (SLE, cryoglobulinemia), infection (hepatitis B/C, syphilis), complement dysregulation; in congenital onset, infection and complement abnormalities are the main causes
3. GeneticsCFH, CFI, C3, CFHR, MCP/CD46 gene variants; AR or sporadic; hereditary causes are rare in the immune complex-mediated type
4. General epidemiologyOverall MPGN incidence 1–2 per million; congenital/infantile onset extremely rare; hepatitis C-related type 1 is common in adults but congenital onset is rare
5. PathophysiologyImmune complex deposition subendothelially in the GBM and in the mesangium + migration of mesangial cells into the GBM (double contour/tram track formation) + persistent complement activation → mesangiocapillary proliferation
6. SymptomsMixed nephrotic syndrome pattern with hematuria + proteinuria + low complement; hypertension; low serum C3 (more common in type 1); systemic symptoms when infection-associated
7. SignsGBM double contour; C3 ± IgG deposits on immunofluorescence; subendothelial deposits (type 1) or mesangial deposits (type 3) on electron microscopy
8. ScreeningMonitoring of complement levels; maternal hepatitis B/C and autoantibody tests; gene panel (complement-related)
9. DiagnosisBiopsy (confirmation of double contour), complement panel, infection and autoantibody tests, genetic analysis
10. TreatmentTreatment of the cause (antiviral, immunosuppression); complement inhibitor (eculizumab); ACE inhibitors/ARBs
11. PrognosisVaries by cause; risk of chronic progression with complement abnormalities; prognostic data for congenital disease are lacking compared with adult MPGN
12. PreventionInfection prevention (hepatitis B/C vaccines, syphilis testing); genetic counseling for complement gene variants
13. References10 key references (with PMID or DOI)

1. History

Membranoproliferative glomerulonephritis (MPGN) is a histologic type characterized on light microscopy by double contours of the GBM ('tram-track' appearance) and mesangial expansion due to migration of mesangial cells into the GBM. In the early 1960s, Habib and Benoit, as well as West and colleagues, independently described this histologic type, and in the 1970s a system classifying it into type 1 (subendothelial deposits), type 2 (dense deposit disease, DDD), and type 3 (mixed subendothelial + subepithelial deposits) became established.

In adults, the most common cause of MPGN type 1 is hepatitis C virus (HCV)-associated mixed cryoglobulinemia, and type 3 has various immune complex-related causes. Type 2 (DDD, Dense Deposit Disease) is currently classified under a separate ICD code (N04.6). In 2012, Sethi and Fervenza proposed a new classification based on immunofluorescence findings, reclassifying it into immune complex-mediated MPGN (Ig deposits + C3) and C3 glomerulopathy (isolated C3 deposits). This classification system bears directly on the pathogenic mechanism and the direction of the treatment approach and is currently widely used internationally.

MPGN type 1 or type 3 with congenital or infantile onset is extremely rare, and complement pathway gene abnormalities are considered the most important cause. Pediatric MPGN cases have been reported in Korea as well, but independent data on congenital onset are very limited.

2. Causes

The causes of congenital nephrotic syndrome with membranoproliferative glomerulonephritis (MPGN types 1 and 3) are broadly divided into the immune complex-mediated type and the complement pathway abnormality type. HCV-associated cryoglobulinemia, common in adults, plays no role in congenital onset, and the spectrum of causes in congenital onset differs from that in adults.

Infectious causes: congenital hepatitis B (vertical transmission from HBsAg-positive mothers), congenital syphilis, CMV, and other TORCH infections can cause an immune complex-mediated MPGN pattern. In these cases, serum complement (C3, C4) is low, and combined deposits of IgG, IgM, and C3 appear on immunofluorescence.

Complement pathway abnormalities: variants in the CFH (complement factor H), CFI (complement factor I), C3, CFHR1–5, and MCP (CD46) genes cause persistent activation of the alternative complement pathway and may present as C3 glomerulopathy (C3GN or DDD) or an immune complex MPGN pattern. Anti-CFH antibodies (associated with CFHR1 deletion) are also a cause. This category is considered important in congenital onset.

Autoimmune causes: cases in which an MPGN pattern appears in neonatal lupus due to maternal antibody transfer have rarely been reported. Transfer of anti-dsDNA antibodies from maternal SLE may be the cause.

3. Genetics

The genetic causes of congenital nephrotic syndrome with MPGN are mainly variants in complement regulatory pathway genes.

Major genes: CFH (1q32.2): autosomal recessive complete deficiency → low C3 and C5, MPGN/aHUS pattern. Autosomal dominant heterozygous variants → incomplete penetrance, aHUS or MPGN. CFI (4q25): AR deficiency → hyperactivation of the alternative complement pathway. C3 (19p13.3): gain-of-function variants (AD) → C3GN/MPGN. CFHR1–CFHR5: gene rearrangements/deletions → production of anti-CFH antibodies, MPGN. MCP/CD46 (1q32.2): deficiency of a cell-surface complement regulatory protein, mainly aHUS.

Genotype-phenotype correlation: infantile-onset MPGN/aHUS is observed in complete CFH deficiency (homozygous nonsense). Congenital or early-onset nephropathy with a C3GN pattern has been reported with gain-of-function C3 variants. Genetic diagnosis is key to decisions on the use of complement inhibitors such as eculizumab. Genetic testing strategy: complement gene panel including CFH, CFI, C3, MCP/CD46, THBD, and CFHR1–5, or WES. Acquired causes are also excluded together with measurement of anti-CFH antibodies.

4. General epidemiology

The overall incidence of MPGN (types 1 and 3) is rare at about 1–2 per million adults, and congenital or infantile onset is an extremely small fraction of these. HCV-associated MPGN is the most common cause in adults but is unrelated to congenital onset, and in pediatric MPGN, complement abnormalities and infections (hepatitis B, syphilis, etc.) are the main causes.

MPGN due to complement pathway abnormalities (CFH deficiency, C3 gain of function) is estimated at 0.5–1 per million, and infantile onset among these is even rarer. Internationally, a small number of pediatric and infant cases have been reported in registry studies of complement abnormality-associated MPGN (C3GN/DDD registry). The number of congenital patients registered under N04.5 in Korea is very small, and they fall within the rare disease management system under Special Copayment Reduction code V263. Overall, far more patients with this subtype exist in adult nephrology, and data on congenital onset worldwide are at the level of case reports.

5. Pathophysiology

The core of the pathophysiology of MPGN types 1 and 3 is the formation of a double GBM through deposition of immune complexes subendothelially (type 1) or subendothelially + subepithelially (type 3) in the GBM and migration of mesangial cells into the GBM (interposition).

Immune complex-mediated mechanism (immunofluorescence Ig+ C3): circulating immune complexes or antibodies against intraglomerular antigens are deposited subendothelially in the GBM. These deposits activate complement (mainly the classical pathway), causing C3 consumption and low C3 (C4 also low), influx of neutrophils and monocytes, and mesangial cell activation. Activated mesangial cells interpose between the GBM and endothelial cells, forming a double contour of the GBM. This appears as the characteristic 'tram-track' finding of MPGN on light microscopy.

Hyperactivation of the alternative complement pathway (C3 glomerulopathy): with CFH/CFI deficiency or C3 gain-of-function variants, C3 convertase is persistently activated and C3b is continuously deposited in the GBM. A serum complement pattern with low C3 only and no reduction in C4 is characteristic. Isolated C3 deposition is observed on immunofluorescence, with absent or minimal Ig deposits (C3 glomerulopathy criterion). Persistent C3 deposition and complement activation cause mesangial cell interposition, GBM double contours, and mesangial proliferation, forming the MPGN pattern.

6. Symptoms

Congenital nephrotic syndrome with MPGN presents as a mixture of nephrotic syndrome and acute nephritic symptoms and is characterized by simultaneous hematuria, proteinuria, hypertension, and low complement.

Renal symptoms: nephrotic-range proteinuria (UPCR ≥ 2.0 mg/mg) and hypoalbuminemia are the nephrotic components, and hematuria (microscopic or gross), hypertension, and reduced renal function are the acute nephritic components. The mixed presentation of these two components is the clinical hallmark of MPGN and suggests MPGN over minimal change disease (pure nephrotic syndrome) or PSGN (pure nephritis). Oliguria and acute kidney injury may occur.

Systemic symptoms when infection-associated: in cases due to congenital hepatitis B, syphilis, or CMV, jaundice, hepatosplenomegaly, skin rash, microcephaly, and the like may accompany it. When associated with complement abnormalities (aHUS overlap), anemia (hemolysis), thrombocytopenia, and reduced renal function may progress rapidly. In infants, poor feeding, growth retardation, and poor weight gain are early clinical clues.

Serum complement abnormalities: low C3 is a very common finding in MPGN and is important for distinguishing the immune complex-mediated type (both C3 and C4 low) from the alternative complement pathway abnormality type (only C3 low, C4 normal).

7. Signs

Physical examination: generalized edema, elevated blood pressure, urine discoloration due to hematuria (brown or red). With infectious causes, jaundice and hepatosplenomegaly. With aHUS overlap, pallor, jaundice, and petechiae.

Laboratory findings: urine: proteinuria (3–4+), hematuria (3+), red blood cell casts. Serum: low C3 (essential finding), C4 low in the immune complex-mediated type (normal with alternative complement pathway abnormalities). Low serum albumin, hyperlipidemia. Elevated creatinine and BUN. CBC: thrombocytopenia, hemolytic anemia (with aHUS). Autoantibodies: ANA, anti-dsDNA (to exclude lupus). Cryoglobulins (to exclude cryoglobulinemia, adult type). Infection tests: HBsAg, HCV Ab (to exclude congenital infection), TORCH, syphilis.

Kidney biopsy findings: light microscopy: double contours of the GBM ('tram-track'), mesangial expansion, narrowing of capillary lumina. Double contours are distinct on PAS and Jones silver stains. Immunofluorescence: types 1 and 3 - subendothelial granular deposits of IgG, IgM, and C3 ± mesangial deposits. C3 glomerulopathy - isolated C3 deposits. Electron microscopy: type 1 - subendothelial electron-dense deposits. Type 3 - combined subendothelial + subepithelial deposits.

8. Screening

Universal screening of the general population is unnecessary. Screening focused on high-risk groups and clinically suspected cases is needed.

Maternal infection screening: immediate HBV immunoglobulin and vaccine administration to newborns of HBsAg-positive mothers. Standard prenatal tests for syphilis, CMV, and TORCH. Monitoring of maternal antibody transfer in mothers with autoimmune disease (SLE).

Monitoring of complement levels: immediate measurement of C3 and C4 in newborns and infants with mixed findings of hematuria + proteinuria + hypertension. With isolated low C3, complement gene panel testing and measurement of anti-CFH antibodies. Evaluation for possible aHUS (triad of thrombocytopenia, hemolytic anemia, and reduced renal function).

9. Diagnosis

Confirmation of congenital nephrotic syndrome with MPGN is made by integrating identification of the MPGN pattern on kidney biopsy, tests for the cause (infection, autoimmunity, complement abnormalities), and genetic analysis.

Clinical and laboratory criteria: the combination of nephrotic-range proteinuria + hematuria + low C3 strongly suggests MPGN. Accompanying low C4 suggests the immune complex-mediated type, and normal C4 + low C3 suggests the alternative complement pathway abnormality type.

Kidney biopsy: confirmation of MPGN and subtype classification by GBM double contours, mesangial expansion, and immunofluorescence and electron microscopy findings. The presence or absence of Ig deposits on immunofluorescence distinguishes immune complex-mediated MPGN (IgG, IgM, C3) from C3 glomerulopathy (C3 alone).

Complement tests: C3, C4, CH50, AH50 (alternative pathway), serum CFH and CFI levels, measurement of anti-CFH antibodies. Complement gene panel (CFH, CFI, C3, MCP/CD46, CFHR1–5) or WES. Serum cryoglobulins (to exclude adult causes).

Tests for the cause: HBsAg, HCV Ab (congenital infection), TORCH panel, syphilis tests. ANA, anti-dsDNA (to exclude lupus). ADAMTS13 activity (to exclude TTP). Platelets, blood smear (to exclude aHUS/TTP).

10. Treatment

Treatment of congenital nephrotic syndrome with MPGN is individualized according to the cause.

Treatment of infectious causes: antiviral treatment (entecavir, lamivudine) when HBV-associated. HCV-associated DAAs (direct-acting antivirals) are rarely indicated in congenital onset. Congenital syphilis and CMV are treated with the corresponding antibiotics/antivirals. After treatment of the cause, normalization of complement and improvement of renal findings are monitored.

Complement inhibition therapy: when CFH deficiency or hyperactivation of the alternative complement pathway is confirmed, eculizumab (a C5 inhibitor) has established efficacy in aHUS. In C3 glomerulopathy, the efficacy of eculizumab is limited, and C3/C5 inhibitors such as avacopan and pegcetacoplan are in clinical trials. In CFH deficiency, CFH can be supplemented temporarily with fresh frozen plasma (FFP) or plasma exchange. Meningococcal vaccination is mandatory when using eculizumab.

Immunosuppressants and supportive care: evidence for steroids, MMF, and cyclophosphamide in immune complex-mediated MPGN is limited, but they are tried in pediatric practice. ACE inhibitors/ARBs suppress proteinuria and preserve renal function. Supportive care for edema, nutritional support, infection prevention, and thrombosis prevention is provided concurrently.

11. Prognosis

The prognosis of congenital nephrotic syndrome with MPGN differs greatly according to the cause and treatment response.

Infectious causes: after treatment of the causative infection, normalization of complement and improvement of renal findings are possible, and some reach complete remission. However, recovery from histologic damage (GBM double contours, mesangial proliferation) may be slow.

Complement abnormality-associated: aHUS due to CFH deficiency carries a high risk of acute renal failure and death without eculizumab treatment. Renal recovery is possible after eculizumab treatment, but there is a risk of relapse if treatment is discontinued. C3 glomerulopathy follows a chronic course, reaching ESRD within 10–15 years in about 30–50%, and the efficacy of complement inhibitors is still at the clinical trial stage.

Kidney transplantation: MPGN carries a risk of post-transplant recurrence (30–50%), and the recurrence rate is especially high with complement abnormalities. Correcting the cause of the complement abnormality before transplantation is important. In CFH deficiency, simultaneous liver-kidney transplantation or kidney transplantation after liver transplantation has been reported as a strategy that provides a source of complement protein and prevents recurrence.

12. Prevention

Prevention of congenital nephrotic syndrome with MPGN centers on prevention of causative infections and genetic counseling for families with complement gene variants.

Infection prevention: prenatal hepatitis B screening and immediate vaccine + immunoglobulin administration to newborns. Prenatal syphilis testing and penicillin treatment. Hygiene education and surveillance for pregnant women at high risk for CMV. Antibody monitoring in mothers with autoimmune disease.

Genetic counseling for families with complement gene variants: prenatal/preimplantation genetic diagnosis in families with confirmed CFH, CFI, or C3 variants. In newborns carrying variants, early complement level monitoring and readiness for immediate eculizumab if aHUS develops (with prior meningococcal vaccination). Decisions to discontinue or continue long-term eculizumab maintenance therapy are based on individualized risk assessment.


13. References

  1. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis — a new look at an old entity. N Engl J Med. 2012;366(12):1119-1131. DOI: 10.1056/NEJMra1108178. PMID: 22435371.
  2. Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: KDIGO Controversies Conference. Kidney Int. 2017;91(3):539-551. DOI: 10.1016/j.kint.2016.10.005. PMID: 28094080.
  3. Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens. 2013;22(2):231-237. DOI: 10.1097/MNH.0b013e32835da3d3. PMID: 23299551.
  4. Rosenblad T, Zuber J, Frémeaux-Bacchi V, et al. Outcome of children with C3 glomerulopathy. Pediatr Nephrol. 2021;36(9):2751-2761. DOI: 10.1007/s00467-021-05001-2. PMID: 33677680.
  5. Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681-696. DOI: 10.1016/S0140-6736(17)30062-4. PMID: 28214399.
  6. Jalanko H. Congenital nephrotic syndrome. Pediatr Nephrol. 2009;24(11):2121-2128. DOI: 10.1007/s00467-007-0633-9. PMID: 17968594.
  7. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529-1561. DOI: 10.1007/s00467-020-04519-1. PMID: 32382828.
  8. Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079-1089. DOI: 10.1038/ki.2013.377. PMID: 24172683.
  9. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis. J Am Soc Nephrol. 2004;15(3):787-795. DOI: 10.1097/01.ASN.0000115702.28859.A7. PMID: 14978182.
  10. Kim JH, Han KH, Lee JM, et al. Genetic and clinical characteristics of childhood-onset nephrotic syndrome in Korea. J Korean Med Sci. 2019;34(6):e55. DOI: 10.3346/jkms.2019.34.e55. PMID: 30799572.